Stryker Corporation (SYK)
Salud / Tecnología médica (dispositivos e implantes)
A medical technology leader across two complementary segments — MedSurg and Neurotechnology (62% of sales) and Orthopaedics (38%, with Mako SmartRobotics as the differentiator) — with organic growth of ~10% (volume +9.9% + price/mix +0.4%) and adjusted earnings per share growing at a double-digit rate. At ~$331 it trades at ~24× adjusted earnings, above the disciplined quality med-tech band. 5-year base case ~$404 (+5%/year): Fairly valued — a quality business with a wide moat, at a full multiple that leaves a modest margin.
- Price
- $330.82
- Intrinsic value (5y, base)
- $404
- Total annual return (5y)
- 5.2%
- Status (nominal)
- Fairly valued
- Margin of safety
- +3%
The essentials
- Two medical technology segments: MedSurg and Neurotechnology (62% of sales, $15,647M FY2025, +15.7% — driven by the Inari Medical acquisition in venous thrombectomy) and Orthopaedics (38%, $9,469M, +4.3%, with Mako SmartRobotics as the robotic differentiator: more than 2 million Mako procedures performed historically).
- Consistent organic growth of ~10.2-10.3% in constant currency (volume +9.9% + price/mix +0.4% in 2025), sustained by the moat of the Mako installed base plus a portfolio of ~5,600 U.S. patents and ~9,000 rest-of-world patents. Adjusted earnings per share (non-GAAP, as reported by the company) grew from $10.60 (2023) to $12.19 (2024) to $13.63 (2025, +11.8%).
- At ~$331 it trades at ~24× adjusted earnings — above the disciplined quality med-tech band (16-22×). 5-year base case ~$404/share → a total return of +5%/year: Fairly valued. The stock fell -19.6% year over year with no clear source of discount beyond tariff noise and legacy hip litigation.
Intrinsic value — two valuation methods
Total return at 5 years: 5.2%/year = 4.1% appreciation + 1.1% dividend. The target price ($404) is ex-dividend; the $20 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $474 · Multiples $342) exceeds the market price ($331).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $331 trades ~3.2% below its value discounted to today (~$342); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($404) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$214.
Thesis
The business
Stryker is a medical technology leader with two complementary segments: MedSurg and Neurotechnology (62% of sales, the growth engine, +15.7% driven by Inari) and Orthopaedics (38%, +4.3%, with Mako SmartRobotics as the differentiator). Organic growth is consistent (~10.2-10.3% in constant currency for two straight years), supported by a moat of installed base plus patents plus regulatory barriers. Adjusted earnings per share (non-GAAP, as reported) grew at a double-digit rate over the last three years ($10.60 → $12.19 → $13.63).
The valuation
A diversified medical technology business is valued on P/E over adjusted earnings (non-GAAP, as reported by the company itself: GAAP plus amortization of acquisition intangibles, goodwill impairments, restructuring charges and the one-time tax effect of the cross-jurisdiction transfer of intellectual property that inflated the 2025 effective rate to 28.1% from ~14% in prior years), within the 16-22× reference band for quality med-tech. At ~$331 it trades at ~24× — above the ceiling of that band, a full multiple.
The base case projects organic growth decelerating gradually from ~10.2% toward ~7.6% by year 5 (the band for a quality compounder, without crediting any acceleration in advance) and adjusted earnings per share compounding at ~10%/year, with the exit multiple compressing to 18.5× — within the disciplined band, not at today's current ceiling. That yields ~$404/share in five years → a total return of +5%/year, of which the dividend (yield ~1.1%, growing) is a minor part.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. At ~$331 Stryker trades at ~24× adjusted earnings, above the disciplined quality med-tech band (16-22×) — there is no clear source of discount (missing buyers or motivated sellers) beyond the short-term noise of tariffs and legacy litigation. The verdict is Fairly valued: a genuinely high-quality business, with a wide moat and consistent growth, but at a full price that does not leave a wide margin. The bear case (pricing pressure plus litigation setbacks plus the multiple compressing to 15×) cuts the value sharply; the bull case (Mako Shoulder plus Inari accelerating plus a re-rating toward 21×) is the upside asymmetry.
What to watch
Four things. Product liability litigation over legacy hip devices (Rejuvenate, ABGII, LFIT, Wright Medical) and the new European Union product liability directive (full effect December 2026) — the legal disconfirmer. The U.S.-China-European Union tariff regime affecting product costs and supply chains. The integration of Inari Medical (venous thrombectomy) and the other 2025 tuck-in acquisitions — whether they accelerate growth or whether operating leverage gets diluted. And the pace of organic growth (~10% today) — whether Mako 4/Mako Shoulder sustain volume or whether pricing pressure from consolidated hospital buyers erodes it.
Educational / informational. Does not constitute investment advice.